Candida endocarditis in two patients.
On the basis of the data currently available, no dogmatic statements can be made about optimal therapy for Candida endocarditis. In those with valve protheses, early surgery should be carefully assessed even though the differences in outcome (17% vs 53% survival) are not yet statistically significant.
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D001021:Aortic Valve / Q000601:surgery; D002177:Candidiasis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D004359:Drug Therapy, Combination; D004696:Endocarditis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D005437:Flucytosine / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000150:complications; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000627:therapeutic use; D014261:Tricuspid Valve / Q000601:surgery
D009761:Nystatin; D000666:Amphotericin B; D005437:Flucytosine